Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 3Phase 3 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 40Recruiting 20Unknown 7Not yet recruiting 6Active not recruiting 6Terminated 3Withdrawn 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Sarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Topotecan × Clear all
NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT00334867 2013-06-28

Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma

Children's Oncology Group

Phase 3 Withdrawn
Sarcoma

Sarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡